Subscribe for Free (RSS + E-mail)

RSS + E-mail

Napa Summit 2013 →
Featured▾
- XSITE 2013 →
Xconomy National
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

ltimmerman

Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.

While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.

Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys running, mountaineering, and fantasy baseball. Having grown up in Wisconsin, he is, naturally, a lifelong fan of the Green Bay Packers and the Wisconsin Badgers.

Recent posts

NanoString Technologies Maneuvers In Line for $86M IPO

NanoString Technologies just started selling its first diagnostic test after 10 years in business, and now it’s getting ready for another milestone—an initial public offering.

The Seattle-based company said today that... Read more »
Zillions of Biotech Conferences Want You. Which Should You Attend?

Biotech industry conferences are happening, somewhere on this green Earth, every day. If you’ve been around a while, and you’ve attended a few, chances are you get invitations, or marketing pitches,... Read more »
Check KUOW’s “Weekday” for Science News

Science news often falls into the trap of becoming “infotainment” designed to generate ratings, and little else. As one essayist in The Guardian recently put it, “freaky copulation techniques in the... Read more »
Matrix Genetics Emerges from Algae Biofuel Wilderness With a Partner

Matrix Genetics is one of those startups that never really got off the ground in its early days, but never died, either. While the Seattle-based company lived on fumes at various... Read more »
Genentech Follows Fast at ASCO as Cancer Immunotherapy Picks Up

Genentech made its name in cancer by creating targeted antibody drugs that zero in on tumor cells while mostly sparing healthy tissue. Now it’s seeking to compete in the next wave... Read more »
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study

Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation... Read more »
Henri Termeer on Startups, Drug Prices, Getting Older (Part 2)

Yesterday, we ran the first part of a wide-ranging interview with Henri Termeer, the legendary biotech entrepreneur and former CEO of Cambridge, MA-based Genzyme. He spoke about what kinds of... Read more »
Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)

Henri Termeer could have easily faded away into obscurity a couple years ago. The biotech pioneer could have relaxed at his oceanside home in Maine, played a little golf. Or, if... Read more »
Dunsire Out at Millennium as Takeda Reorganizes, Cuts Costs

[Updated: 10:25 pm ET] Deborah Dunsire, the CEO who led Millennium Pharmaceuticals to prominence in cancer treatment, is leaving the company in an abrupt departure five years after it... Read more »
Dendreon Shares Fall Again, as Provenge Sales Slump

Dendreon has made a habit of disappointing investors, and it did so again today.

The Seattle-based biotech company (NASDAQ: DNDN) said today it generated $67.6 million in first quarter sales... Read more »
Genomic Health Test Aims To Cut Overtreatment of Prostate Cancer

Many men in the U.S. hear the words “prostate cancer” and freak out. They want to fight. But a lot of times, the aggressive treatments they demand are unnecessary, expensive, and... Read more »
Lessons For Drug Development From The Aveo Buzzsaw

Drug development is a tough business. Small companies that dare to try often end up in public train wrecks when they head to Washington to meet the FDA. It’s a shame,... Read more »
NW Biotech Education Group Faces Loss of Federal Money, Deep Cuts

The Northwest Association for Biomedical Research (NWABR), a nonprofit that fosters science education and public understanding of research in Washington, Oregon, and Idaho, is contemplating the deepest cuts in... Read more »
Savara Enters the Proving Ground With Inhalable Antibiotic for CF

Patients with cystic fibrosis can expect to live until their late 30s or early 40s. It’s a big improvement over the life expectancy they had a decade or two ago. But... Read more »
Natera Grabs $55M For Push into Prenatal Genetic Screening

Two months after jumping into the market with a non-invasive prenatal screening test for Down syndrome and other genetic disorders, San Carlos, CA-based Natera is raising a lot of investment cash... Read more »
Qiagen Buys Ingenuity Systems, Biology Software Player, for $105M

Ingenuity Systems, a 15-year veteran of the biological software business, showed today that you can make money not just by generating DNA data, but by helping scientists figure out what... Read more »
Six Reasons Why Illumina Has Nothing to Fear from Thermo/Life

Illumina doesn’t need luck. But the San Diego-based company just caught a break this month, which will make it easier to continue crushing all who dare challenge its supremacy in genomics.... Read more »
Forma Strikes $200M Deal With Celgene to Discover Cancer Drugs

Forma Therapeutics has never had trouble finding partners who want access to its early-stage drug discovery team, when most companies are cutting back there. But the Watertown, MA-based company is entering... Read more »
Gen9, Synthetic Biology Startup, Snags $21M from Agilent

[Updated: 1:15 pm ET] Scientists have been able to order up custom-synthesized genes on demand for quite a few years now. But if synthetic biology is going to move... Read more »
Biotech Execs Aren’t Ready to Prove Drugs Have Value, E&Y Says

The U.S. Supreme Court upheld the Affordable Care Act last year as constitutional. President Obama won re-election. After years of runaway spending on healthcare, the well established policy on healthcare in... Read more »

Page 1 of 168 next page »